CVS Health (CVS) PT Raised to $70 at Mizuho

Mizuho analyst Ann Hynes raised the price target on CVS Health (NYSE: CVS) to $70.00 (from $58.00) while maintaining a Outperform rating.

The analyst commented: "We are publishing our final models for the managed care group following Q4:24 earnings, to take into account reported results and publication of the 10-Ks. Overall, we are making only modest changes to adjusted EPS and lowering our price target on UNH as we no longer believe the company can trade at prior multiples given the market volatility. For CVS, we are raising our price target to $70 given the embedded earnings power of the company."

You May Also Be Interested In

• Standard Nuclear (STDN) PT Raised to $20 at UBS
• Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'
• Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'